News

GenomEra SARS-CoV-2 Assay Kit is now CE IVD approved and development for four-in-one test (FluA, FluB, RSV, SARS-CoV-2) is on-going

17.7.2020

GenomEra SARS-CoV-2 Assay Kit is now CE IVD approved and available. Please contact your local distributor or us for more information.

In addition, we are developing a four-in-one test for detecting influenza A, influenza B, RSV and SARS-CoV-2. Targeted release is before winter Flu season 2020-2021.
Investment round is now open

5.6.2020

We warmly welcome all new investors!
#Crowdfunding #CapitalAtRisk

https://abacusdiagnostica.com/invest

We have been ramping-up the production of SARS-CoV-2 test and #GenomEra instruments. Also we just opened an investment round at: https://t.co/RAxNTQXNtT

Have a look to to see our long term plans for new fully auto #POC platform combining #PCR and #Immunoassays #CapitalAtRisk
— Abacus Diagnostica (@AbacusCDX) June 4, 2020
Special approval granted for SARS-CoV-2 test

4.5.2020

Finnish regulatory authority Fimea has granted special approval for Abacus to supply the GenomEra RUO SARS-CoV-2 test to Finnish markets.

Press release in Finnish
First SARS-CoV-2 Test Kits Shipped

30.3.2020

Our team has been working hard on past weeks and today we shipped first GenomEra SARS-CoV-2 test kits for our customers.

Press-release in Finnish: https://bit.ly/2UvaMC2
Abacus is now on Twitter

26.3.2020

Abacus is now on Twitter! We will tweet the latest news and more relaxed stories frequently. Some big news coming next week – stay tuned! https://twitter.com/AbacusCDX #AbacusCDX

Our CE #IVD approved GenomEra CDX is rapid and affordable #molecular #diagnostics solution for decentralized testing of infectious diseases. Minimalistic GenomEra Test Chip are containing all (RT-)#qPCR reagents.#myfirstTweet pic.twitter.com/QjAcraZnKm
— Abacus Diagnostica (@AbacusCDX) March 26, 2020
Recent publication: GenomEra C. difficile test demonstrates increased reliability for standalone molecular diagnostics

11.3.2020

While covid19 is spreading, there are still other worries to deal with. Standalone PCR testing for C. difficile diagnostics is often criticized for overdiagnosis of CDI. In a recent publication (doi:10.1128/JCM.01872-19) GenomEra routine samples were retested with two different toxin immunoassays and discrepant results were confirmed with culture or GeneXpert. Results shows perfect 100% PPV and excellent 99.7% NPV for GenomEra. Study reports insufficient sensitivities of 81.6% and 71.7% for two different toxin immunoassay from ArcDia and TechLab, respectively.
Announcement of a new distributor

28.1.2020

We are proud to announce our new distributor:

-NexGen Molecular Supplies, South Africa.

Please visit https://www.abacusdiagnostica.com/distributors/ to view the complete list. #pcr #abacusdiagnostica #molecular #diagnostics
New results from MRSA/SA AC and S.pneumoniae tests compared to culture.

16.1.2020

Poster P-124 from #Ricai 2019 poster session demostrates a study by Manon Prat et.al how our tests GenomEra MRSA/SA AC and GenomEra S.pneumoniae perform when suspected of superinfection with #influenza and #RSV. Using an optimized protocol and clinical samples, our tests correlate 100% with culture results. #moleclardiagnostics #pcr #poitiers #abacusdiagnostica #GenomEra
Season´s greetings

20.12.2019

We at Abacus Diagnostica would like to thank you and especially all our distributors and partners for this year and we all wish you a peaceful holiday season and a happy new year 2020! #pcr #moleculardiagnostics #seasonsgreetings #happynewyear
Abacus Diagnostica at Medica 2019!

25.10.2019

We will attend Medica next month in Düsseldorf. To book a meeting with us, please contact sales@abacusdiagnostica.com. We will be present the whole exhibition. See you there!